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Background: Lynch syndrome is an inherited disorder associated with a range of cancers, and found in 2–5 % of
colorectal cancers. Lynch syndrome is diagnosed through a combination of significant family and clinical history
and pathology. The definitive diagnostic germline test requires formal patient consent after genetic counselling. If
diagnosed early, carriers of Lynch syndrome can undergo increased surveillance for cancers, which in turn can
prevent late stage cancers, optimise treatment and decrease mortality for themselves and their relatives. However,
over the past decade, international studies have reported that only a small proportion of individuals with suspected
Lynch syndrome were referred for genetic consultation and possible genetic testing. The aim of this project is to
use behaviour change theory and implementation science approaches to increase the number and speed of
healthcare professional referrals of colorectal cancer patients with a high-likelihood risk of Lynch syndrome to
appropriate genetic counselling services.
Methods: The six-step Theoretical Domains Framework Implementation (TDFI) approach will be used at two large,
metropolitan hospitals treating colorectal cancer patients. Steps are: 1) form local multidisciplinary teams to map
current referral processes; 2) identify target behaviours that may lead to increased referrals using discussion
supported by a retrospective audit; 3) identify barriers to those behaviours using the validated Influences on Patient
Safety Behaviours Questionnaire and TDFI guided focus groups; 4) co-design interventions to address barriers using
focus groups; 5) co-implement interventions; and 6) evaluate intervention impact. Chi square analysis will be used
to test the difference in the proportion of high-likelihood risk Lynch syndrome patients being referred for genetic
testing before and after intervention implementation. A paired t-test will be used to assess the mean time from the
pathology test results to referral for high-likelihood Lynch syndrome patients pre-post intervention. Run charts will
be used to continuously monitor change in referrals over time, based on scheduled monthly audits.
Discussion: This project is based on a tested and refined implementation strategy (TDFI approach). Enhancing the
process of identifying and referring people at high-likelihood risk of Lynch syndrome for genetic counselling will
improve outcomes for patients and their relatives, and potentially save public money.
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Identification and referral of patients with a relevant
clinical or family history of cancer can save the lives of
those affected by hereditary cancers [1]. Lynch syndrome
(LS), an inherited disorder involving many types of
cancer, is found in 2–5 % of colorectal cancers (CRCs)
[2, 3]. Globally, there were an estimated 1.36 million
new cases of CRC in 2012, with 134,349 in the United
States and 40,775 in the United Kingdom [4]. In
Australia there were around 17,000 new CRC cases in
2014 and this figure is projected to rise to around 20,000
by 2020 [5]. CRC (and other cancer) patients identified
as being at high risk of LS can be referred for genetic
counselling to Family Cancer Clinics (FCCs) where a
definitive genetic test can be undertaken with the pa-
tient’s consent. This enables carriers to engage in effective
screening protocols, detect and treat cancer early, and
educate relatives. Early diagnosis of LS is therefore critical
since surveillance (e.g., colonoscopic) and/or risk reducing
surgery for LS patients and at-risk relatives can prevent
cancer, optimise medical management and reduce mortal-
ity [6, 7]. Although LS has been detected in a relatively
small proportion of CRC patients (5 %), tens of thousands
are believed to carry a LS gene in Australia alone, making
LS an extremely underdiagnosed condition [8].
Whilst clinicians cannot be expected to have detailed
knowledge about causative LS genes, current guidelines
from Australia, the United States and Europe emphasise
their responsibility for recognising the clinical phenotype
and family history characteristics of LS, and referring pa-
tients to clinical genetics or family cancer clinics if
deemed necessary [9–14]. Referral is required as cur-
rently in public health, the definitive diagnostic test must
be ordered by a specialised FCC and requires formal pa-
tient consent after genetic counselling. However, over
the past decade, local and international studies have re-
ported that only a small proportion of individuals with
suspected LS were referred for genetic consultation and
possible genetic testing [8, 15–18]. In particular, recent
Australian evidence indicates that over half (54 %) of
patients with CRC with a high likelihood of LS were not
referred for genetic testing, despite indicators recom-
mending referral [19]. Unidentified carriers remain
unaware of their greater cancer risk or the need for on-
going screening. Relatives may also miss the opportunity
to discover if they have LS. These delays in detecting
and managing cancer may lead to significant morbidity
and loss of life.
Implementation of clinical guidelines which aim to
facilitate the translation of research evidence into prac-
tice require healthcare professionals to change their
behaviour. Whilst behaviour change is complex, [20]
emphasised by a growing field of research dedicated
to understanding and improving healthcare, [21] it isentirely possible [22]. The application of behaviour
change methods to design interventions, such as iden-
tifying and addressing key barriers to change, [23] can
transform healthcare organisations and improve pa-
tient outcomes [23, 24]. Whilst some evidence exists
for the factors affecting clinical decisions and actions
for patients who may benefit from screening to detect LS,
[10] the development and implementation of evidence-
based interventions to address health care professionals’
barriers to referring patients with CRC with a high-
likelihood of LS for genetic testing is lacking. Using
approaches such as intervention co-design with key stake-
holders can enhance intervention generalisability across
different contexts, and the translation of effective ap-
proaches from research into practice [25].
The validated, six-step Theoretical Domains Framework
Implementation (TDFI) approach [26] uses behaviour
change theory and implementation science principles to
identify and address key barriers to changing clinical
practice. Barriers are represented by 11 domains of behav-
iour change, e.g., ‘knowledge’, ‘skills’, ‘social influences’,
‘emotion’, ‘environment’, ‘professional role and identity’,
‘memory, attention, decision processes’. These domains
are based on theoretical constructs from multiple psycho-
logical and organisational behaviour change theories [24].
Authenticating a bottom-up strategy with senior manage-
ment support, the TDFI approach takes a team of front-
line health care professionals supported by behavioural
scientists through a collaborative implementation process.
We have successfully used this approach to demonstrate
clinical, statistical and cost-effective improvements in
guideline implementation (e.g., for anaesthetics, enteral
feeding) across UK hospitals [20, 22, 26]. In this project we
will use the validated TDFI approach in two large Austra-
lian hospitals to improve the timely identification of LS in
patients with CRC. This represents an opportunity to ad-
dress a known clinical problem and unmet need through
the application of a behavioural change approach.
Methods/Design
Overview
We will use the TDFI approach in two large Australian
metropolitan hospitals to: 1) form health care profes-
sional implementation teams and process map LS refer-
rals; 2) conduct baseline audits of CRC surgery patients
and LS genetic testing referrals to identify target behav-
iours for change; 3) use the validated Influences on
Patient Safety Behaviours Questionnaire (IPSBQ) [20]
and undertake TDF-guided focus groups with health
care professionals to identify and verify referral barriers
(e.g., knowledge, environment/resources, memory, emo-
tion); 4) co-design interventions with health care profes-
sionals using evidence-based strategies to address key
barriers; 5) co-implement interventions; and 6) evaluate
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practice and culture change (see Fig. 1).
Recruitment
Hospital recruitment (preliminary work)
The project team secured commitment in principle from
two large metropolitan Australian hospitals and associ-
ated healthcare organisations involved in the LS referral
process (i.e., hospitals, Family Cancer Clinics, and path-
ology laboratories) whilst forming the project plan as
part of a translational research funding application. This
was achieved by liaising with key stakeholders (i.e., hos-
pital oncologists, pathologists, and genetics counsellors)
to identify if and how the context-specific problem could
be addressed through this behaviour change implemen-
tation approach. Upon receiving notification of the fund-
ing award, the project team have confirmed hospital
participation through invitations to participate and via
ethics and site-specific governance procedures, which
require authorising signatures from senior management
at each organisation.
Staff
The process of recruiting staff to the implementation
teams is described in step 1 of the procedure. Recruit-
ment of health care professionals for self-report psycho-
social measures of perceived barriers to behaviour
change will use implementation team organisational
networks, as described in Taylor et al. [22, 26]. All staff
for whom the key behaviour is relevant (e.g., colorectal
surgeons and medical oncologists, pathologists, and cancer
nurses) will be targeted.
Procedure
Step 1 – Implementation team selection
We will identify, through referral and expression of
interest, up to 10 multidisciplinary change agents [27] at
each of the hospitals to form an implementation team






















Fig. 1 The Theoretical Domains Framework Implementation Approach [26]assist in: mapping and critiquing the current process;
gathering audit data; introducing the project to the vari-
ous components of the referral process; and identifying
possible target behaviour(s) for change (e.g., methods of
reporting or disseminating pathology results, use of guide-
lines to inform referral decisions, referral methods).
Step 2 – Audit of current practice
We will audit the following data to identify baseline
evidence of current referral processes: 1) number and
date of colectomy samples received from patients with
CRC by each local pathology service; 2) number and
date of mismatch repair (MMR) deficient tumours de-
tected through immunohistochemistry (IHC) which are
associated with LS, identified in these resected speci-
mens; 3) number and date of referrals to the FCC for
genetic counselling about testing for LS; 4a) number of
patients who chose to take a genetic test, and of those
patients, 4b) number diagnosed with LS, and number
not diagnosed with LS (including dates of results). De-
tails on the wording of the pathology report received by
the treating health care professionals such as whether LS
is mentioned and any recommendations for referral to
the FCC will be noted. This information will allow the
team to identify the proportion of patients with CRC
with high-likelihood risk of LS, compared to the number
of referrals made for genetic testing; i.e., the accuracy
of referral practices (see Table 1), as well as the speed
of referrals, and define the target behaviour(s) for
change. This data will also be used to identify post-
intervention implementation changes in referral prac-
tices and speeds.
Step 3 – Identification of barriers to change
The validated IPSBQ [20] will be distributed to ap-
proximately 25 health care professionals involved in
the LS referral process (e.g., CRC surgeons, oncologists,
pathology laboratory staff, FCCs) in each hospital, in both
















Table 1 Matrix demonstrating the information that data
collection will provide regarding accuracy of LS referral practices
LS risk status Referred Not referred
Patients with CRC with high likelihood of LS ✓ ✗
Patients with CRC with low likelihood of LS ✗ ✓
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memory, emotion) to performing the target behaviour(s)
according to the domains of the TDF. Following analysis
of the questionnaire data, stage 1 of TDFI-guided focus
groups will be undertaken with healthcare professionals to
discuss key barriers to clinical practice change in detail.
Step 4 – Development of solutions to overcome barriers
Stage 2 of the TDFI-guided focus groups will consist of
project team members working with staff to devise
context-relevant interventions to overcome key barriers
using their expertise in evidence-based behaviour change
strategies (e.g. [28, 29]) and implementation science (e.g.
[30, 31]) methods. This development phase will involve
consultation with our consumer networks to gain a pub-
lic perspective on the intended intervention content and
function.
Step 5 – Implementation of solutions
A report outlining the process, findings, and suggested
interventions will be submitted to senior management in
each hospital. Following authorisation for implementa-
tion, the project team, with support from the implemen-
tation team, will implement intervention strategies.
Step 6 – Evaluation
Monthly collection of pathology and referral data will be
undertaken to assess the impact of interventions and to
allow for refinements. Pre-post intervention data analysis
will be undertaken by the project team to determine the
impact of the intervention on the proportion of high-
likelihood LS risk CRC patient referrals for LS testing,
and speed of referrals. Post-intervention implementation
the IPSBQ will be used to assess changes in perceived
healthcare professional barriers to referring high-
likelihood risk of LS patients for genetic testing.
Measures
Access to patient data and data collection staff
The heads of pathology for each participating site will fa-
cilitate access to retrospective and prospective pathology
data for all the MMR deficient tumours identified
through routine IHC testing. A senior genetic counsellor
(RW) will facilitate access to referral data in the FCC
database. A pathology registrar (EE) with clinical author-
isation to access hospital pathology data will be respon-
sible for undertaking this aspect of the data collection.Identifying the proportion of high-likelihood risk patient
referrals
MMR deficient tumour data will be cross-referenced
against the number of CRC patient LS referrals using
the FCC database. This will identify the proportion of
high-likelihood risk of LS cases (denominator) compared
to the number of referrals made for genetic testing
(numerator).
Identifying the speed of referrals
Pre-post intervention implementation samples of high-
likelihood risk of LS patients who were referred for
testing will also be identified, and (where available) the
calendar dates of events occurring within the referral
process (e.g., tumor resection, identification of MMR
deficient tumours, referral recommendation, date refer-
ral received by genetics to discuss genetic testing) will be
recorded. This will allow us to determine the change in
the speed of referral for genetic testing from the initial
recognition of pathology test results.
Identifying health care professionals’ perceptions of barriers
to referral
The validated IPSBQ [20] will be distributed to rele-
vant health care professionals pre-post implementa-
tion through steering group members. This will allow
us to identify change in the perceptions of barriers to
referral.
Analysis plan
Proportion of high-likelihood LS risk patient referrals
We will use Chi square to test: a) the difference in the
proportion of high-likelihood LS patients being referred
for genetic testing before and after intervention imple-
mentation, and b) to detect changes in the sensitivity of
the system [i.e., for the number of referrals of individuals
with the genetic mutation (true positive), compared with
the number of referrals made for individuals who do not
have the genetic mutation (false positive)]. Throughout
the course of the project, we will use run charts to con-
tinuously monitor change in referrals over time, based
on the scheduled monthly audits. This will provide in-
sights into which aspects of the implemented interven-
tions are effective.
Speed of referrals
A paired t-test will be used to assess the mean time
from the pathology test results to referral for high-
likelihood LS patients before and after the interven-
tion. Where possible, we will also assess for effects of
moderators on overall outcomes, such as where path-
ology test results are sent, or by which type of clin-
ician a referral is made.
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Inter-item correlations will be used to test for internal
consistency of each subscale of the IPSBQ, with values
above 0.15 to 0.50 being the optimal range. Criterion
validity will be established by comparing mean total
questionnaire scores against audited referral rates in
each organisation. Multivariate analysis of variance
(MANOVA) will be used to assess the difference in per-
ceived barriers post-intervention implementation, after
controlling for baseline differences.
Trial status
Data collection for this study is ongoing. Of the six-step
process described above, Steps 1–3 (recruitment of
implementation teams, generation of a process map,
retrospective audit, and collection of the IPSBQ ques-
tionnaire) have been completed. Step 4 is underway.
Discussion
This project is based on a refined, tested collaborative
implementation strategy that will be applied to identify
and overcome key healthcare professional barriers to ap-
propriately referring patients with a high-likelihood risk
of hereditary cancer genes for genetic testing. It will
introduce regular monitoring of LS referral practices to
participating organisations, thereby increasing awareness
of LS and the potential for sustained, improved referral
practice. By applying and refining the tested TDFI
approach, for the first time within the Australian health-
care system and with healthcare professionals to im-
prove cancer care, we expect to improve the current
rates of referral for genetic testing in New South Wales
(NSW) from 46 % [19] to ensure those patients with
CRC with a high likelihood of LS are rapidly identified
and provided with the opportunity to have the definitive
genetic test. This is expected to lead to better cancer
prevention through the provision of opportunities for
more frequent targeted screening, and access to surgical
procedures to remove tissues and organs at higher risk
of LS related cancers, [6] resulting in improved patient
outcomes, including gains in years of life [32].
In addition to improved patient outcomes, by increas-
ing the number of high-likelihood LS referrals for gen-
etic testing, the TDFI approach may also save public
money. For example, tumour testing for LS (on which
referrals are based, alongside other factors such as family
history) is cost effective in the UK, with all incremental
cost-effectiveness ratios below the National Institute for
Health and Care Excellence threshold of <£20 K(Aus$36 K)
per quality adjusted life year (QALY) gained [32]. Other
potential outcomes might include: improved service
coordination, more effective organisational functioning,
improved inter-professional collaboration and communi-
cation between health care professionals, improved healthcare professional job satisfaction with improved patient
outcomes, reductions in crisis work with late detection
and removal of life threatening cancers. Overall the
outcomes of each of these advances will serve to benefit
patients through improved evidence-based surveillance
and faster treatment.
To disseminate the findings of the project we will
develop a strategy for effectively sharing lessons and re-
sources within and between participating organisations,
and with other healthcare organisations in Australia
and internationally. This might involve, for example,
liaising with key local, national, and international cancer
networks (e.g., translational research networks, cancer
agencies including the Cancer Institute New South
Wales and consumer agencies such as Lynch Syndrome
Australia) to devise ways for communicating the out-
comes of this work into community based and academic
settings. These activities will enable interventions devel-
oped and lessons learned through this work to be shared
with healthcare organisations and the wider community
both within and beyond the participating hospital net-
works to improve referral patterns of patients with CRC
with high-likelihood risk of LS.
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